Login / Signup

In vivo gene immunotherapy for cancer.

David MaiCarl H JuneNeil C Sheppard
Published in: Science translational medicine (2022)
Cancer is becoming increasingly understood not only as a disease of pathological cells but also as one of immune hypofunction. The heterogenous and patient-specific nature of cancer further underscores the need for personalized cellular therapies, which are currently produced ex vivo. Gene-modulating approaches, such as therapeutic RNAs and improved viral vectors, now bring us closer toward strategies for mitigating disease, particularly for diseases that benefit from altering gene or transgene expression profiles in pathological or therapeutic immune cells. An advancing toolbox of technologies and trends toward simplifying personalized therapies foreshadow opportunities for direct, in vivo precision medicine against cancer.
Keyphrases
  • papillary thyroid
  • squamous cell
  • copy number
  • genome wide
  • sars cov
  • induced apoptosis
  • squamous cell carcinoma
  • gene expression
  • signaling pathway
  • oxidative stress
  • young adults
  • cell cycle arrest